Inflammatory markers and cardiometabolic diseases.
Acta Clin Belg
; 70(3): 193-9, 2015 Jun.
Article
in En
| MEDLINE
| ID: mdl-26103538
ABSTRACT
OBJECTIVES:
A growing body of evidence emerges that obesity, metabolic syndrome, type 2 diabetes and cardiovascular disease are intimately related to chronic inflammation.METHODS:
A narrative review summarizing the most recent data of the literature describing the pathological implications of inflammation in obese patients with cardiometabolic disorders.RESULTS:
Besides high-sensitive C-reactive protein, various circulating or in situ inflammatory markers have been identified, presumably reflecting the presence of inflammation in various key-organs (visceral adipose tissue, skeletal muscle, pancreatic islets, liver, intestine, arterial wall). Available data support the concept that targeting inflammation, not only reduces systemic inflammatory markers, but also improves insulin sensitivity and ameliorates glucose control in insulin-resistant patients, thus potentially reducing the risk of cardiovascular complications.CONCLUSION:
These observations confirm the role of inflammation in cardiometabolic diseases and support the development of pharmacological strategies that aim at reducing inflammation, especially in patients with type 2 diabetes.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
C-Reactive Protein
/
Cardiovascular Diseases
/
Metabolic Syndrome
/
Diabetes Mellitus, Type 2
/
Inflammation
/
Obesity
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Acta Clin Belg
Year:
2015
Document type:
Article